The Medicare Drug Price Negotiation Program is set to go into effect Jan. 1, 2026, and without changes it’s set to cause significant damage to independent pharmacies. NCPA’s Ronna Hauser, senior vice president of policy and pharmacy affairs, sat down with Antonio Ciaccia, president of 3 Axis Advisors, to review his firm’s new research outlining the lost revenue, cash flow disruptions, and below-cost reimbursements that will hammer small and independent pharmacies for an episode of NCPA’s Independent Rx Forum podcast. Listen to the episode here or wherever you get your podcasts.
NCPA
